One note before the checklist itself. Everything on this page concerns research and laboratory use only. Tirzepatide as discussed here is not intended for human consumption, and nothing on this page is medical advice — speak to a doctor or pharmacist for anything concerning your own health. What follows is a literacy tool for evaluating a research batch, not a guide to using one.
We built this file as a checklist rather than a narrative because that's closer to how the actual decision gets made. Nobody reads a single essay and reaches a verdict — a researcher works through a short list of questions, one at a time, and a listing either survives each one or it doesn't. Eight checks on the batch itself, five signals that mean stop and ask more, and a short honest note on how a parcel actually reaches a Dublin address.
What tirzepatide actually is
Tirzepatide is a dual agonist — a single peptide engineered to act on two separate receptor pathways, GIP and GLP-1, rather than one alone. That dual mechanism is the research interest in a sentence: earlier compounds in this general class typically targeted the GLP-1 pathway on its own, and the question behind a dual agonist is whether adding the GIP pathway changes outcomes meaningfully or simply adds another variable to account for.
It sits in a broader wave of multi-receptor metabolic peptides moving through research and clinical pipelines at the same time — our retatrutide file covers a related triple-agonist compound further along a similar research question, if the comparison is useful. The two aren't interchangeable and shouldn't be treated as substitutes for each other in a research plan, but the underlying logic — more receptor pathways, more variables, more caution warranted before treating early listings as settled science — carries across both.
Supplied as a lyophilised powder for laboratory reconstitution, tirzepatide is sold and studied on the research-peptide market the same way the other compounds on this register are: as a research chemical, not a finished product intended for use in or on the human body.
Research-grade, not the medicine already on pharmacy shelves
Tirzepatide is a slightly different case from BPC-157 on this register, because its underlying molecule already exists elsewhere as a prescription-only medicine holding marketing authorisation for specific approved indications, dispensed through a pharmacy under a doctor's supervision. That licensed product and the research-grade material discussed on this page are not the same thing, even though both are built on the same molecule and share a name.
The distinction our semaglutide file walks through in full applies here too: a finished, licensed medicine goes through a formal authorisation process, arrives with a patient information leaflet, and is dispensed by a pharmacist who has checked it against a prescription. Research-grade tirzepatide does none of that — it's a laboratory compound, sold and bought as one, with an independent Certificate of Analysis standing in for every piece of paperwork the licensed side takes for granted.
Ireland's medicines regulator, the HPRA, licenses the pharmacy product through that same authorisation process — but the licence has no bearing on how a research-grade batch from an unrelated supplier should be evaluated. Confusing the two is the single most common mistake we see researchers make on this specific compound, precisely because — unlike BPC-157, or retatrutide for now — there's a licensed product with the same underlying molecule already familiar to buyers, and it's an easy shortcut to assume the paperwork carries across. It doesn't.
The batch documentation checklist
Six checks, in the order we'd actually work through them against a listing or a document a supplier hands over.
The mechanism claim is stated correctly
The listing describes tirzepatide as a dual GIP/GLP-1 agonist, not a generic "GLP-1 peptide" or a compound it isn't. A supplier vague about which receptors a molecule acts on is often vague about testing it, too.
Regulatory status is stated honestly
The material is described plainly as research-grade, with no blurring toward the licensed pharmacy product or its approved indications. Careful wording here tends to predict careful wording everywhere else.
A lot number is present and matches
The Certificate of Analysis carries a specific lot number, and that number matches what's printed on the product you'd actually receive — not a generic document reused across every batch a supplier has sold.
Purity is reported by HPLC, with the method stated
A bare percentage sitting on its own proves very little. The method — high-performance liquid chromatography — should be named on the document, not just the number it produced.
Identity is confirmed by LC-MS
Purity tells you how clean a sample is; it says nothing about whether it's the right molecule at all. A liquid chromatography–mass spectrometry result confirming the molecule matches tirzepatide's expected mass is the test doing the real work.
The testing laboratory is named and independent
A laboratory you can look up, with no financial relationship to the seller. A results sheet produced by the seller's own in-house team is a specification, not third-party verification, however professional it looks.
Red flags: when to stop and ask more questions
Five signals that repeat across the weaker tirzepatide listings we come across — several of them the same patterns our BPC-157 file lists, because the underlying dishonesty doesn't really change from one compound to the next.
A COA that never changes between batches
Same numbers, same formatting, batch after batch. Real testing produces real variation; a document that never moves is a template, not a report.
Clinical-sounding claims on unlicensed material
Language like "clinically proven" or "trial-backed" attached to a research-grade listing borrows the authority of the licensed product without earning it. Treat it as a reason to slow down, not a reassurance.
A lot number that doesn't appear on the product
If the number on the COA can't be found anywhere on what actually arrives, the document and the vial have no verifiable connection to each other.
Pressure to pay before documentation is shown
Promised paperwork is not the same as provided paperwork. A seller confident in their batch hands over the COA without friction, before payment, not after.
Pricing well below the range a tested batch would cost
Independent HPLC and LC-MS testing has a real cost. A price that doesn't reflect it is usually a sign the testing didn't happen — a reason to look harder, not to celebrate a bargain.
Getting a batch to a Dublin address
Where a tirzepatide batch ships from changes the buying experience without changing the underlying documentation standard — the same principle our home page walks through for the register generally, restated briefly here because tirzepatide buyers ask about it just as often as everyone else.
A supplier fulfilling domestically moves a parcel through familiar courier networks, usually reaching a Dublin address within a day or two with straightforward tracking. A supplier based outside Ireland ships further, the parcel may pass through customs handling along the way, and the timeline stretches — sometimes by a week or more — with a less predictable handoff between carriers.
Neither route tells you anything about what's actually inside the vial. A well-documented batch can travel from either direction, and an undocumented one can arrive overnight from a supplier a few kilometres away. Ask about the ship-from location and the expected transit window before you pay, by all means — but treat it as logistics planning, not a verification step. The checklist above is the verification step.
This file sits alongside three others on this register, each built to its own structure — a five-entry dossier for BPC-157, a side-by-side data table for semaglutide, and a timeline for retatrutide. Different formats, the same underlying standard: read the documentation for the specific batch in front of you before you trust anything a listing claims about it.
We keep the single source we've reviewed against this checklist behind one clearly marked page, separate from every guide on this register.
See the verified source